A Phase Ib/II Study to Investigate the Safety , PK and PD of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis
Latest Information Update: 04 Mar 2025
At a glance
- Drugs SHR-1819 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Guangdong Hengrui Pharmaceutical
Most Recent Events
- 25 Feb 2025 Planned number of patients changed from 36 to 50.
- 25 Feb 2025 Status changed from not yet recruiting to recruiting.
- 06 Dec 2024 New trial record